TWA
HRTX icon

TCI Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

TCI Wealth Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-745
Closed -$4K – 2382
2022
Q1 		$4K Buy
+745
New +$5.45K ﹤0.01% 1713
2021
Q2 		– Sell
-112
Closed -$2K – 2372
2021
Q1 		$2K Buy
+112
New +$2K ﹤0.01% 1765

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCI Wealth Advisors's HRTX Position: Q2 2022 in Review

TCI Wealth Advisors sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 745 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in HRTX in Q1 2021 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • TCI Wealth Advisors reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 745 Heron Therapeutics shares in Q2 2022, an estimated $4K.
  • TCI Wealth Advisors first reported a position in Heron Therapeutics in Q1 2021 and held it in 2 quarters.
  • TCI Wealth Advisors's Heron Therapeutics position peaked at $4K in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on TCI Wealth Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.